Gericke introduces GFS Gen3
A continuous manufacturing platform designed to make pharmaceutical production faster, simpler, and safer. A platform approach built to support compliant manufacturing from clinical studies through long term production.
Gericke today announced the launch of the Gericke Formulation Skid GFS Gen3, a new continuous manufacturing platform for the formulation of OSD. It is designed to help pharmaceutical manufacturers progress faster, operate more simply, and maintain high levels of safety as process requirements evolve.
Across the pharmaceutical industry, manufacturers face increasing pressure to progress efficiently while managing changing volumes, responding to containment needs, and growing regulatory expectations. Traditional batch approaches often rely on multiple systems and repeated qualification work, creating complexity, delays, and risk as processes move from one stage to the next.
GFS Gen3 was developed to address these challenges through a platform based approach to continuous manufacturing — enabling a consistent process philosophy from early development through commercial production. The result is a system designed around three core principles:
Fast
From clinical studies to production with fewer disruptions. GFS Gen3 supports a single continuous manufacturing approach that can progress from early trials to long term production within one platform architecture. By reducing unnecessary transitions between equipment types, the system helps teams maintain momentum and shorten the path from development to the patient.
Simple
Precision setup made easy. With a streamlined design focused on usability and repeatable alignment, GFS Gen3 simplifies setup and product changeovers. The platform’s focus on precise, consistent operation helps minimize variability and operational complexity — supporting reliable performance over the lifecycle of a product.
Safe
Containment aligned to process needs. GFS Gen3 incorporates scalable containment options, from basic dust control to advanced high containment solutions. This process aligned approach supports operator safety, regulatory compliance, and smooth day to day operation as production requirements evolve. “At its core, GFS Gen3 reflects a different way of thinking about continuous manufacturing,” said Bernhard Meir, Head of Continuous Manufacturing of OSD, Gericke. “We designed the platform so that containment, precision, and regulatory readiness reinforce each other — giving teams confidence as they progress, without unnecessary disruption.”
GFS Gen3 is built as a platform rather than a one size fits all solution. Different flexible and modular configurations can support different operational priorities — such as development focused agility or efficient long term production — while maintaining a consistent underlying approach to process control, containment, and compliance.
“We deliberately avoided designing a rigid system,” added Bernhard. “GFS Gen3 supports controlled evolution over time — recognizing that pharmaceutical manufacturing must be able to move forward without starting over.”
